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Familial partial lipodystrophy (FPLD) results from coding
sequence mutations either in LMNA, encoding nuclear lamin
A/C, or inPPARG, encodingperoxisomeproliferator-activated
receptor  (PPAR). The LMNA form is called FPLD2 (MIM
151660), and the PPARG form is called FPLD3 (MIM 604367).
We now report a 21-yr-old female with FPLD and no coding
sequence mutations in either LMNA or PPARG. She was het-
erozygous for a novel A>Gmutation at position 14 of intron
B upstream of PPARG exon 1 within the promoter of the
PPAR4 isoform. Her less severely affected father, who had
features of the metabolic syndrome and a paucity of limb and
gluteal fat, was also heterozygous for14A>G. This mutation
was absent among 600 alleles from normal Caucasians. Amin-
imal promoter sequence bearing the mutation had signifi-
cantly reduced promoter activity when used to drive reporter
expression in in vitro expression in two cell lines, compared
with thewild-type sequence.This is the first report of ahuman
mutation in the promoter of a PPAR isoform. Because the
mutation affects PPAR4 expression and is associated with
FPLD, this implies that PPAR4 might be important for fat
depot distribution andmetabolism in vivo. (J Clin Endocrinol
Metab 89: 5655–5660, 2004)
DUNNIGAN-TYPE FAMILIAL PARTIAL lipodystro-phy (FPLD; MIM 151660) is considered to be a mo-
nogenic model of the common syndrome of insulin resis-
tance, or metabolic syndrome (1). FPLD is a genetically
heterogeneous autosomal dominant phenotype character-
ized by repartitioning of adipose tissue and is associatedwith
multiple metabolic disturbances. FPLD results from coding
sequencemutations either in LMNA, encoding nuclear lamin
A/C, or in PPARG, encoding peroxisome proliferator-acti-
vated receptor  (PPAR) (1). The LMNA form is called
FPLD2 (MIM 151660), and the PPARG form is called FPLD3
(MIM 604367). The presence of lipodystrophy in subjects
with dysfunctional PPARG missense mutations, such as
R425C, F388L, V290M, and P467L (2–5), and in PPAR-
deficient murine models (6, 7) has confirmed the central role
of PPAR in adipogenesis.
The tissue expression of PPAR mRNA is complex: four
PPARG mRNA isoforms, called PPAR1, 2, 3, and 4 (8–
10), result from different promoter usage and alternative
splicing. A map of the mRNA isoforms and promoters of the
PPAR isoforms is shown in Fig. 1. PPAR1 and PPAR3
mRNAs are relatively widely expressed (8, 11, 12), whereas
PPAR2mRNA is expressed exclusively in adipose tissue (8,
13), suggesting that it is functionally important for that tis-
sue. Primer extension studies have confirmed that PPAR4
mRNA is also present in adipose tissue (9). However, little
is known of PPAR4’s potential role in adipocyte biology or
metabolism. We now present human genetic evidence sug-
gesting that the PPAR4 isoform has a role in adipocyte
biology. Specifically, in a subject with FPLD3, we found a
rare PPARGmutation within the PPAR4 promoter that was
associated with decreased promoter activity in two cell lines.
Subjects and Methods
Study subjects
FPLD proband. The proband was a 21-yr-old Dutch female. Menarche
occurred at age 11, and she has had regular menstrual cycles since then.
At about age 13, she was noted to have grossly abnormal fat distribution
consistentwith FPLD.At age 20, shewas diagnosedwith type 2 diabetes,
and was treated with metformin (1500 mg daily). On examination, she
was obese: weight, 109 kg; height, 178 cm; and body mass index (BMI),
34.4 kg/m2. Waist and hip circumferences were 130 and 114.5 cm,
respectively, with a ratio of waist to hip circumference of 1.14. Her
resting blood pressure was 140/65 mmHg. Clinically, she had excess sc
fat on the face, neck, trunk, and abdomen, with relative lack of sc fat on
the gluteal region, arms, and legs. This was confirmed with magnetic
resonance imaging (Fig. 2), which showed excessive and relatively sym-
metrical deposition of sc fat on the face, neck, and upper trunk, with
disproportionate depletion of sc fat in the lower body, especially dor-
sally in the gluteal region and thigh. She had no acanthosis nigricans or
hirsutism. Measurements in fasting plasma included: glucose, 8.5
mmol/liter (153 mg/dl); insulin, 19 mU/liter (normal, 11 mU/liter);
C-peptide, 1.22 nmol/liter (normal, 0.9 nmol/liter); total cholesterol,
4.1 mmol/liter (159 mg/dl); triglycerides, 0.94 mmol/liter (85 mg/dl);
high-density lipoprotein cholesterol, 0.88 mmol/liter (34 mg/dl); and
low-density lipoprotein cholesterol, 2.83 mmol/liter (110 mg/dl). Based
on the 2001 National Cholesterol Education Panel (NCEP) criteria (14),
she had the metabolic syndrome. DNA sequence of the exons, intron-
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exon boundaries, and flanking regions of her LMNA gene, using a
described procedure (15), was normal.
Proband’s father. Her father was 56 yr old and apparently healthy, al-
though he reported a sister and paternal female first cousin with similar
physical appearance to the proband. On examination, he was over-
weight: weight, 94 kg; height, 186 cm; and BMI, 27.2 kg/m2. The cir-
cumferences of hiswaist and hipwere 110 and 103 cm, respectively, with
a ratio of waist to hip circumference of 1.07. His resting blood pressure
was 132/78 mm Hg. Like his daughter, he had relative depletion of sc
fat from the arms, legs, and gluteal area, with limited truncal fat, al-
though the phenotype was much less severe than that of his daughter.
Fasting plasma determinations included: glucose, 4.8 mmol/liter (86
mg/dl); insulin, 8mU/liter; C-peptide, 0.74 nmol/liter; total cholesterol,
5.8 mmol/liter (224 mg/dl); triglycerides, 1.7 mmol/liter (153 mg/dl);
high-density lipoprotein cholesterol, 1.0 mmol/liter (38 mg/dl); and
low-density lipoprotein cholesterol, 4.07 mmol/liter (158 mg/dl). Based
on the 2001 NCEP criteria (14), he had the metabolic syndrome. DNA
sequence of the exons, intron-exon boundaries, and flanking regions of
his LMNA gene, using a described procedure (15), was normal.
Other subjects. The proband’s 47-yr-old mother and 18-yr-old brother
were each clinically and biochemically normal, with normal fat distri-
bution. Neither had clinical or biochemical criteria for diagnosis of the
metabolic syndrome. Three hundred additional control DNA samples of
FIG. 1. Organizational structure of the PPARG gene on chromosome
3p25 and the four PPAR mRNA isoforms. Arrows, Start site of
transcription for the specific mRNA isoform. Exons are indicated as
boxes on the genomic map. The schematic structure of the four mRNA
isoforms is shown under the genomic map. Exons A1 and A2 are
untranslated, and exon B is translated. PPAR1, 3, and 4 mRNAs
translate into a 477-amino-acid protein. PPAR2 mRNA translates
into a 505-amino-acid protein with 28 extra amino acids at the N-
terminal end.
FIG. 2. Magnetic resonance imaging
(MRI) tissue scans of the proband at
various anatomical sites. A, Sagittal
scan of the neck, with the arrow show-
ing a prominent dorsal suprascapular
sc fat pad; B, cross-section at the level
of the upper thorax, with the arrow
showing a layer of dorsal sc fat mea-
suring 4.84 cm at the thickest point; C,
cross-section at the abdomen, showing
a symmetrical circumferential layer of
sc fatmeasuring 7.59 cm at the thickest
point; D, cross-section at the right glu-
teal region, with the large arrow show-
ing concavity of dorsolateral sc fat pad
and the small arrow showing paucity of
dorsal sc fat, measuring 0.5 cm at its
thickest point; E, cross-section at the
rightmidthigh, with the arrow showing
paucity of dorsal sc fat, measuring 0.3
cm at its thickest point; F, cross-section
of the right leg, showing a thin layer of
sc fat. The scans are consistent with
excess sc fat deposition centrally in the
upper body, with relative lack of sc fat
on extremities and gluteal region and
preferential loss of fat dorsally in the
lower body.
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normal subjects of European descent without diabetes or the metabolic
syndrome were studied to determine mutation frequency.
DNA analysis
Participants from The Netherlands provided informed consent, and
all genetic analyses were performed with approval from the University
of Western Ontario Ethics Review Board. PPARG was amplified from
the proband’s genomic DNA. Oligonucleotides were designed using
genomic DNA sequences of human PPARG obtained from GenBank
accession numbers AB005520–AB005526, AF548352, and AY043357 and
from published sequences (8, 9, 16). PPARG primers spanned all trans-
lated exons, namely exon B and exons 1–6, with more than 50 nucleo-
tides at each intron-exon boundary, 400 bp of the PPAR2 promoter, 660
bp that spanned the PPAR3 promoter and exon A2, and the 433-bp
PPAR4 promoter. Amplified fragments were purified on a 2% agarose
gel (QIAquick Gel Extraction Kit; Qiagen, Mississauga, Ontario, Can-
ada). Direct DNA sequencing was carried out using the dideoxynucle-
otide chain termination method with the designed primers, with elec-
trophoresis on a Prism 377 Automated DNA Sequencer and analysis
using Sequence Navigator software (both from Applied Biosystems,
Mississauga, Ontario, Canada).
To detect rapidly the PPAR4 promotermutation in three first-degree
relatives of the proband and in 300 control DNA samples, an allele-
specific method called SNaPshot (Applied Biosystems) was used (17).
The sequence of the common amplification primer was 5-CTG GGA
TAACAGGTG TGAGCCA. The sequence of the bracketing primer for
the wild-type promoter was 5-TTT CTG AAA GGA AAA ATA GAC
TAG CTG TG. The sequence of the bracketing primer for the mutant
promoter was 5-TTT CTG AAA GGA AAA ACA GAC TAG CTG TG
(mutated nucleotide shown in bold and underlined). The SNaPshot primer
sequence was 5-GGA CTT AAC TTC ACA GCT AGT CT. The proce-
dure was performed as described, with fragment analysis using Ge-
neScan Software (Applied Biosystems).
In vitro expression studies
Expression vector constructs. The PPAR4 promoter was amplified from
subjects with and without the 14AG mutation using primers. All
sequences for promoter studies were derived from GenBank number
AY043357. Purified 436-bp products representing wild-type and mu-
tated PPAR4 promoter were ligated into the pCR2.1 vector using the
TA Cloning Kit protocol (Invitrogen, Carlsbad, CA). Plasmid DNA was
prepared using the Qiagen kit (Qiagen), and sequencing identified a
clone with a perfect forward (53 3) wild-type promoter sequence, a
clone with a perfect reverse (33 5) wild-type promoter sequence
(antisense), and a clone with a perfect forward (53 3) mutation pro-
moter sequence. After digestion with endonucleases SacI and XhoI, the
inserts were directionally subcloned in the luciferase reporter PGL3
basic vector (Promega, Madison, WI). After transfection and purifica-
tion, sequencing was used to confirm orientation and fidelity of purified
plasmid DNA samples for three types of constructs: 53 3 wild-type,
33 5 wild-type, and 53 3 mutation.
Cell lines and culture.Murine cell lines NIH/3T3 (CRL-1658) and 3T3-L1
(CL-173) were obtained from American Type Culture Collection (Ma-
nassas, VA). The overall strategy for in vitro expression studies was
described previously (18). Cells were maintained in a DMEM (Invitro-
gen) containing 4.5 g/liter d-glucose, 1.5 g/liter NaHCO3, 25 mm
HEPES, 4 mm l-glutamine, and 110 mg/liter sodium pyruvate in a
humidified atmosphere of 95% air-5% CO2 at 37 C. Medium was sup-
plemented with 100 U/ml penicillin, 100 mg/ml streptomycin, and 10%
heat-inactivated fetal bovine serum (Invitrogen). Each cell line was
grown on a 100-mm culture dish (Nunclon; Nalge Nunc, Mississauga,
Ontario, Canada). Cells were seeded on six-well plates to achieve 60%
confluence and transfected using calcium phosphate precipitation with
one of the three PPAR/Luc reporter constructs. For each transfection,
2 g pSV--galactosidase vector was cotransfected according to man-
ufacturer’s instructions (ProFection Mammalian Transfection Systems,
Promega). Cells were harvested 48 h post transfection. Transfection
experiments were repeated in triplicate, three times on separate days for
each cell line. Luciferase activity was assayed according to the manu-
facturer’s instructions (Promega), and luminescence was determined
using a Lumat LB9507 luminometer (Berthold Systems, Pittsburgh, PA).
Luciferase activities were normalized for transfection efficiencies using
reporter luciferase units (RLU) per unit of activity of -galactosidase
(B-Gal). The -galactosidase enzyme assay system was used according
to manufacturer’s directions (Promega).
Statistical analysis
SAS version 6.12 (SAS Institute, Cary, NC) was used for statistical
analysis. A two-way ANOVA was performed using the general linear
model computing procedure of SAS, with independent variables being
single-nucleotide polymorphism type (wild-type or mutation) and ex-
periment number (first, second, or third experiment). The dependent
variable was RLU/B-Gal. Because transfection was done in triplicates in
each experiment, each ANOVA cell had three data points.
Results
Identification of mutation in promoter of PPAR4 isoform
In the genome of the proband, we found a heterozygous
nucleotide substitution in PPARG intron B, 14AG up-
stream of exon 1 within the PPAR4 promoter (9). All other
regions were free of DNA sequence changes. By genotyping,
we found that this mutation was also present in the het-
erozygous father but was absent from the genomes of her
unaffected mother and brother and also from 300 normal
Caucasian controls. Furthermore, our DNA sequence anal-
ysis revealed that the PPAR4 promoter consists of 433 bp
rather than 432 bp, as previously published (9), with the
difference in size attributable to an extra A nucleotide at
position 383 of intron B. This 433-bp sequence length was
confirmed in an additional 10 control DNA samples.
PPAR4 promoter activity
Adjusted (least squares) means of normalized luciferase
activities from triplicate experiments performed on three
different days are shown in Fig. 3. Compared with wild-type
promoter, the mutant promoter had 60% decreased normal-
ized luciferase activity in 3T3 cells (P  0.05) and 70% de-
creased activity in 3T3-L1 cells (P  0.0001).
Discussion
In the PPARG gene of a probandwith the FPLDphenotype
and type 2 diabetes and marked fat repartitioning, we found
the 14AG heterozygous mutation in the promoter of
PPAR4. The clinical phenotype of the subject was notable
for a relative excess of sc fat centrally in the upper body and
a relative paucity of fat in the gluteal region and extremities,
especially dorsally (Fig. 2). This mutation was also found in
the genome of her less severely affected father but neither in
her clinically normal mother nor brother nor among the
genomes of 300 normal Caucasian control subjects. In vitro
expression studies showed that this mutation resulted in a
significant reduction in promoter activity in both 3T3 and
3T3-L1 cell lines, the latter of which is an adipogenic cell line
derived from mouse Swiss 3T3 fibroblasts (19, 20). The find-
ings suggest that noncoding mutations in PPARG are asso-
ciated with partial lipodystrophy and implicate the PPAR4
isoform as being potentially important in adipocyte biology.
Because the mutation is in PPARG, this patient and father
have FPLD3.
Differential splicing of PPARG gives rise to four distinct
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mRNA isoforms, called PPAR1, 2, 3, and 4, respectively
(Fig. 1). PPAR1, 3, and 4 mRNA species give rise to the
identical 477-amino-acid protein, whereas PPAR2 mRNA
gives rise to a 505-amino-acid protein with 28 extra N-
terminal amino acids (8–10). Although the expressed protein
is the same for each mRNA isoform, the differences in the
promoters and noncoding exons result in differential tissue
expression. For instance, thewell-studied PPAR2 isoform is
primarily expressed in fat and is considered to be the key
isoform related to adipose metabolism. In contrast, the re-
cently characterized PPAR4 isoform, though also expressed
in fat, has largely unknown metabolic attributes. Expression
studies to identify tissue distribution and relative quantity of
the PPAR4 mRNA have not been possible because the
PPAR4 nucleotide sequence is common to all four PPAR
mRNA isoforms. At minimum, it is known that PPAR4
mRNA is present in human adipose tissue, because it was
detected there by primer extension analysis of total RNA (9).
The current findings indicate that deficiency of the PPAR4
isoform resulting from diminished expression in carriers of the
14AG mutation is associated with partial lipodystrophy.
The PPAR4 promoter contains a TATA-like sequence at
nt 170 to 166, an AP-1 site at position nt 187 to 184,
and a retinoic acid receptor-related orphan receptor response
element (RORE) at position nt 303 to 298, all relative to
the start site of transcription (9). The latter element has been
proven to be regulatory, because overexpression of ROR1,
which specifically binds to RORE, resulted in a 40-fold in-
crease in promoter activity in transient transfection assays in
several cell lines (9). However, the14AGmutation is not
located within RORE or in any potential regulatory element.
Instead, the mutation is very close to the transcription ini-
tiation site and, as such,may affect the transcription initiation
complex machinery. Alternatively, an unknown transcrip-
tion factor might fail to bind and transactivate transcription
in the presence of the 14AG mutation. Detection of such
a DNA binding protein would require EMSA, which is be-
yond the scope of this report. However, our findings high-
light the importance of more careful characterization of the
PPAR4 promoter.
The proband’s phenotype was consistent with that seen in
other female heterozygotes for coding sequencemutations in
PPARG. To date, four missense mutations in PPARG result-
ing in PPAR deficiency have been shown to cause partial
lipodystrophy, namely R425C (2), F388L (3), and V290M and
P467L (4, 5). Clinical features of these patients and the two
subjects with the 14AG mutation are shown in Table 1.
Careful examination of subphenotypes (also called phe-
nomic examination) has shown that patients with PPARG
mutations (FPLD3) have a distinctive phenotype including a
specific distribution of adipose tissue loss, relatively severe
biochemical and clinical signs of insulin resistance, and rel-
atively early onset of type 2 diabetes. There have been sug-
gestions that the biochemical phenotype in PPAR defi-
ciency is out of proportion to the extent of adipose loss,
compared with LMNA-associated partial lipodystrophy (1,
3). This would suggest that, in addition to adipose tissue
redistribution, PPARG mutations may have additional in-
dependent effects on metabolism.
Furthermore, there appeared to be a difference in pheno-
typic severity in the PPAR4 14AG proband and her
father. Specifically, the proband’s father had a relativelymild
clinical and biochemical phenotype, which contrasted with
the proband’s more striking phenotype. This appears to be
FIG. 3. In vitro expression studies of wild-
type and mutant PPAR4 promoter. Normal-
ized RLU/B-Gal are shown for three sets of
triplicate experiments for two cell lines: 3T3
(A) and 3T3-L1 (B). Adjusted (least squares)
means  SE values are shown for luciferase
reporter constructs containing wild-type
PPAR4 promoter, a negative control con-
struct made by cloning of wild-type promoter
in the reverse orientation, and a construct con-
taining the14AGmutation.Asterisks, Sig-
nificant difference between mean normalized
expression from wild-type and mutant con-
structions (*, P  0.05; **, P  0.0001).
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consistentwith observations in the small numbers of PPAR-
deficient subjects studied so far (2–5). For instance, female
carriers of the PPARG F388L mutation appeared to be more
severely affected, with respect to anthropometry, hyperten-
sion, and dyslipidemia, than male carriers (3). Similar, be-
tween-sex differences in phenotype severity have been noted
in LMNA-related partial lipodystrophy (1, 21). Although in-
teresting, the anecdotal nature of the between-sex differences
in phenotypic severity in PPAR deficiency and in partial
lipodystrophy precludes speculation regarding potential
mechanisms. Ascertainment of additional subjects and fam-
ilies and specific physiological studies are required.
Finally, we cannot exclude the possibility that there is a
defect at another genetic locus that interactswith the PPAR4
14AGmutation. For instance, Savage and colleagues (22)
described heterozygosity for a loss-of-function premature
stop mutation in PPARG in a large Caucasian European
kindred. However, in that family, the PPARG defect alone
was not associated with an abnormal metabolic phenotype.
Instead, subjects who were doubly heterozygous for the
PPARG defect together with a defect in a separate unrelated
gene had severe insulin resistance (22). In an analogousman-
ner, therefore, it is possible that the haploinsufficiency re-
sulting from the PPAR4 14AG mutation requires a sec-
ond genetic defect for the affected subjects to express their
disease. In our sample, the search for such a second defect is
limited by the small family size.
In summary, we have found a rare loss-of-function mu-
tation in the promoter of PPAR4 in a proband with partial
lipodystrophy. This extends the range of PPARG mutations
(23) and indicates that noncoding mutations in PPARG are
associated with the FPLD3 subtype of partial lipodystrophy.
Furthermore, the findings provide additional confirmation
of the concept that PPAR deficiency is a cause of partial
lipodystrophy with associated metabolic disturbances. Fi-
nally, the findings implicate the PPAR4 isoform as being
potentially important in adipocyte biology.
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